FDA OKs Merck tablet to reduce grass allergies

Merck & Co. says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old.

Meant as an alternative to weekly allergy shots, the tablet dissolves under the tongue. Taken daily for a few years, it gradually reduces sensitivity to common grasses, instead of temporarily relieving symptoms including sneezing, runny nose, and itchy, watery eyes.

Merck, based in Whitehouse Station, N.J., will market the in North America. Its partner, ALK-Abello, sells it in Europe as Grazas.

Merck said Grastek will be available in U.S. pharmacies in late April. However, it's best to start taking it three months before grass pollen season begins.

The drug can cause severe allergic reactions and shouldn't be used by patients with severe asthma.

© 2014 The Associated Press. All rights reserved.

Citation: FDA OKs Merck tablet to reduce grass allergies (2014, April 15) retrieved 20 April 2024 from https://medicalxpress.com/news/2014-04-fda-oks-merck-tablet-grass.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Canada approves Merck grass allergy immunotherapy

 shares

Feedback to editors